PRESENTATION

Q3 2021 — Presentation

Q3 2021PDF · 38 pages2.3 MB
Merck
Q3 2021 Earnings
October 28, 2021

-- 1 of 38 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chief Executive Officer
Human Health
Results
Frank Clyburn
President, Merck
Human Health
Question & Answer
Session
Animal Health and
Financial Results
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 38 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
3
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products, including if the Acceleron
acquisition is consummated, Acceleron’s pipeline products, that the products will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; uncertainties as to the timing of the offer and subsequent
merger with Acceleron; uncertainties as to how many of Acceleron’s stockholders will tender their shares in the offer; the risk that competing offers or
acquisition proposals will be made; the possibility that various conditions to the consummation of the merger and the offer contemplated thereby may not be
satisfied or waived; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency
of the transactions on Acceleron’s business; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of
defense, indemnification and liability; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global
outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s
patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 3 of 38 --

Strategy &
Business Update
Rob Davis
Chief Executive Officer

-- 4 of 38 --

Delivered on our key strategic priorities in 3Q 2021
5
Achieved strong commercial and
financial performance
Advanced the pipeline to meet patient
unmet need
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 38 --

Merck’s investigational antiviral treatment has potential to
have meaningful impact on the COVID-19 pandemic
6
• 	Demonstrated a 50% reduction in risk of
hospitalization or death in phase 3 MOVe-OUT trial
in at risk, non-hospitalized adults with mild-to-
moderate COVID-19
• 	Submitted EUA and engaging with FDA as the
agency reviews application. Announced EMA rolling
submission.
• 	Governments and health systems around the world
recognizing potential and committing to orders
upon regulatory approval
• 	Rapidly building supply to meet expected demand

-- 6 of 38 --

Acceleron acquisition adds strong external science and
potential long-term growth driver in sotatercept
7
• 	Transaction aligns well with innovation-driven
business development strategy
• 	Sotatercept is a first-in-class, late-stage asset with
potential to be foundational pulmonary
hypertension add-on therapy
• 	Potential multi-billion dollar commercial
opportunity with ability to drive long-term revenue
growth
• 	Significant potential to positively impact patients
and create shareholder value

-- 7 of 38 --

2019 	2020 	2021
$41.5B
+8%
GUIDANCE
RANGE
$47.4B–$47.9B
+13% to +14%
$39.1B*
2019 	2020 	2021
$4.53
+25%
GUIDANCE
RANGE
$5.65 - $5.70
+23% to +24%
$3.73*
Revenue
EPS
Exceptional Q3 2021 sales and earnings growth
8
$13.2B
+19%
Growth rates exclude the impact of foreign exchange.
* Growth rate not available as restated 2018 results are not provided
Worldwide Sales
$1.75
+26%
Non-GAAP EPS

-- 8 of 38 --

ESG priority areas grounded in the core values
that guide Merck’s mission
9
Access to
health Employees
Environmental
sustainability
Ethics
& values
• Access to medicine
• Product quality and safety
• Public health risks
• Climate change
• Employee health and safety
• Employee engagement
and diversity
• Business ethics
• Ethics in R&D
• Data security and privacy
• Governance structures
and mechanisms

-- 9 of 38 --

Human Health
Results
Frank Clyburn
President, Merck Human Health

-- 10 of 38 --

Human health delivered continued strong performance in Q3
11
• 	Sustained business
momentum driven by
strong underlying demand
and commercial execution
• 	Continue to invest in
patient activation
programs
• 	Lingering effects from
the pandemic remain a
modest headwind
Growth rates exclude the impact of foreign exchange.
Total Human Health
$11.5B, +17%

-- 11 of 38 --

Oncology: KEYTRUDA drives continued momentum
12	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $4.5B increased 21%
year-over-year, driven by momentum across
key tumor types and recent launches
– In the U.S., sales of $2.6B driven by growth across
all key tumor types, including continued
leadership in lung, as well as RCC, TNBC, MSI-H,
esophageal, and H&N
– Ex-U.S., 24% growth was driven by global uptake
in lung as well as RCC and H&N
• KEYTRUDA will continue to expand into earlier
lines of therapy
– In the U.S., more than half of KEYTRUDA’s
growth will come from indications in earlier-stage
treatment settings through 2025, and will
represent roughly 30% of total KEYTRUDA sales
3Q19 	3Q20 	3Q21
$3.7B
$3.1B
$4.5B
+21%
+64%
+21%

-- 12 of 38 --

Oncology: Additional current and future growth drivers
• Lynparza sales increased 25%, with growth
driven by breast and continued uptake in other
approved indications, including ovarian and
prostate
• Lenvima sales grew 30%; growth in the U.S.
driven by RCC and EC; ex-US growth driven by
NRDL listing in China
• WELIREG launch off to a strong start with
approval in patients with certain VHL-
associated tumors, potential to expand to
broader RCC indications in the future
Growth rates exclude the impact of foreign exchange.
3Q19 	3Q20 	3Q21
$196M
$123M
$246M
3Q19 	3Q20 	3Q21
$142M
$109M
$188M
13
+58%
+>100%
+25%
+29%
+>100%
+30%

-- 13 of 38 --

Vaccines: GARDASIL robust global demand
14
• GARDASIL sales of $2.0B, increased 63%
year-over-year, driven by strong global
demand and increased supply
– U.S. growth benefited from timing of CDC
purchases and underlying demand
– Ex-U.S., growth was driven by robust demand,
increased supply and reallocation of doses
Growth rates exclude the impact of foreign exchange.
3Q19 	3Q20 	3Q21
$1.2B
$1.3B
$2.0B
-10%
+27%
+63%

-- 14 of 38 --

Hospital: BRIDION strong performance
15
• BRIDION sales of $369M increased 15%
year-over-year, driven by increased share
of the growing neuromuscular blockade
reversal market
• Continued uptake in PREVYMIS, driven by
ongoing launches
• ZERBAXA expected to return to market
in Q4
Growth rates exclude the impact of foreign exchange.
3Q19 	3Q20 	3Q21
$320M
$284M
$369M
+13%
+32%
+15%

-- 15 of 38 --

Trends to watch: GARDASIL and Oncology
16
• Sustained robust underlying demand, particularly
in ex-US markets such as China
• Normal business seasonality will make Q3 the
largest quarter of sales in 2021
• Global HPV vaccination levels remain low in
eligible patient cohort
• Continue to benefit from investments in
manufacturing productivity and capacity which
will better position us to meet long-term global
demand
• KEYTRUDA maintains very strong IO class
leadership
• KEYTRUDA growth from new indication
launches, offsetting continued softness in new
patient starts as a result of the pandemic
• Confident in the underlying demand across our
broad and innovative Oncology portfolio
• Indications in early-stage disease will account for
greater than half of KEYTRUDA’s growth
through 2025
GARDASIL 	Oncology

-- 16 of 38 --

Trends to watch: Molnupiravir commercial considerations
17
• Potential first oral treatment option authorized
for mild or moderate COVID-19
• Enable greater access by entering into
agreements with voluntary license manufacturers
and Medicines Patent Pool covering >100
countries, and by using a tier-based pricing
approach
• Announced several supply and purchase
commitments
• Ongoing discussions with other governments
around the world
Key Considerations 	Enabling Broad Global Access
• 	Supply and purchase commitments with Australia, Korea, New
Zealand, Serbia, Singapore, United Kingdom and United States
Supply and purchase commitments
Potential access through VL/MPP agreements

-- 17 of 38 --

Trends to watch: Pneumococcal vaccine franchise
CDC’s ACIP votes to provisionally recommend the regimen of VAXNEUVANCE + PNEUMOVAX 23
as an option for appropriate adults at increased risk of invasive pneumococcal disease* (IPD)
Strong immune response
for serotypes in vaccine
Robust immune response
data across recommended
cohorts
Broad serotype coverage to
help protect against
majority of IPD cases
Burden of disease
for key serotypes
VAXNEUVANCE elicits robust immune response
to the serotypes in the vaccine, including superior
immunogenicity vs. PCV13 to serotype 3,
the #1 disease-causing serotype in U.S. adults
* Final recommendations are subject to review by CDC director and Department of Health and Human Services, and are pending publication in CDC’s Morbidity and Mortality Weekly Report (MMWR)
Together with PNEUMOVAX23, this regimen
covers key IPD-causing serotypes and provides
the broadest available serotype coverage
among adult pneumococcal vaccines
18

-- 18 of 38 --

Financial Results
Caroline Litchfield
Chief Financial Officer

-- 19 of 38 --

Strong Q3 2021 sales growth
20
Merck
WORLDWIDE SALES1
$13.2B+20% growth
+19% ex-exchange
$11.5B
+18% growth
+17% ex-exchange
Human Health
$1.4B
+16% growth
+14% ex-exchange
Animal Health
1. Worldwide Sales includes Other Revenue.

-- 20 of 38 --

Animal Health: durable growth across portfolio
21
• Animal Health sales increased 14% to $1.4B,
reflecting growth across geographies and
species
– Companion Animal sales increased 18%, driven by
the BRAVECTO parasiticide line of products and
vaccines
– Livestock sales increased 12%, reflecting higher
global demand for ruminant and poultry products,
including Animal Health Intelligence products
Growth rates exclude the impact of foreign exchange.
3Q19 	3Q20 	3Q21
$1.2B
+12%	$1.1B
+12%
$1.4B
+14%

-- 21 of 38 --

Q3 2021 non-GAAP financial results summary:
Delivered strong revenue and EPS growth
Q3 2021 	Q3 2020 	Change Change
Ex-FX
Sales 	$13.2 	$10.9 	+20% 	+19%
Non-GAAP Gross
Margin1 76.8% 	76.5% 	+0.3pts 	+0.3pts
Operating Expenses 	$4.7 	$4.2 	+12% 	+11%
Tax Rate 	13.0% 	14.4% 	-1.4pts 	N/A
Non-GAAP EPS that
excludes certain items 1 $1.75 	$1.37 	+28% 	+26%
$ in billions, except EPS amounts
22
1. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying
business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand
how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with
other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a
substitute for or superior to, information prepared in accordance with GAAP.

-- 22 of 38 --

Updated full-year 2021 guidance1
1. Guidance assumes the Acceleron transaction will close during the fourth quarter. Guidance does not include the impact of the potential launch of molnupiravir.
2. GAAP Gross Margin Rate: Higher than 2020 by a low single-digit rate. 3. GAAP Operating Expenses: Lower than 2020 by a mid-single-digit rate. 4. GAAP Tax Rate: ~14.5% - 15.0%
5. The GAAP to non-GAAP reconciliation is available in Merck’s Q3 2021 earnings release
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $46.4 to $47.4B
+12% to +14% (+10% to +12% ex-FX)
$47.4 to $47.9B
+14% to +15% (+13% to +14% ex-FX)
• Now assumes 1.5% positive FX impact
• Assumes ~3% negative impact due to COVID-19,
particularly during the first half of 2021
Non-GAAP
Gross Margin Rate 2 	76.0-77.0% 	~76.5%
Non-GAAP
Operating Expenses 3 	Increase by high single-digit rate 	Increase by high single-digit rate
• 	Increased promotional spend and patient
activation as well as increased investment in the
pipeline
Other (Income) / Expense 	~$300M of expense 	~$450M of expense 	• 	Increase driven by pension settlement costs
Tax Rate4 	~14.5-15.5% 	~14.0-14.5% 	• 	Driven by discrete items
Shares Outstanding 	~2.53B 	~2.54B 	• 	Assumes very modest repurchase
GAAP EPS5 	$4.24 to $4.34 	$4.71 to $4.76
Non-GAAP EPS5 	$5.47 to $5.57
+21% to +23% (+19% to +21% ex-FX)
$5.65 to $5.70
+25% to +26% (+23% to +24% ex-FX) • Assumes ~2% positive FX impact
23

-- 23 of 38 --

Modeling assumptions & outlook
24
Molnupiravir 	GARDASIL 	Animal Health 	Operating Margin
• 	Potential sales or
earnings for
molnupiravir not
included in 2021
guidance
– Merck shares profits
equally with Ridgeback
– Merck records revenues
and costs
– Profit share reflected in
Cost of Sales
• 	Assuming EUA in
December, expect global
opportunity of ~$5 to
$7B through 2022,
including ~$0.5 to $1.0B
in 2021
• 	Expect robust growth
for GARDASIL in the 4 th
quarter and full year
driven by strong demand
and increased supply
– 4Q 2021 sales will be
lower than 3Q 2021, due
to normal seasonality and
timing effects
– Recall, $120M benefit in
4Q 2020 from CDC
stockpile replenishment
• 	Expect strong long-term
demand-driven growth
– Enabled by increased
capacity
• 	Exceptional quarterly
growth in 2021 driven in
part by increased pet
adoption and pet
spending due to the
pandemic
• 	Expect 4Q 2021 growth
to be more normalized
as these trends stabilize
• 	3Q operating margin
benefitted from strong
revenue growth and
normal seasonality of
vaccines
• 	Expect operating
margins to normalize
due to this seasonality
and phasing of spend
• 	Continue to expect
operating margins of
>42% in 2024

-- 24 of 38 --

Balanced approach to capital allocation in Q3
25
Well positioned balance
sheet with capacity to
fund additional
value-enhancing
business development
opportunities
$2.2
$1.2
$1.6
$0.1
$0.6
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions
Order of priority
1. The business development figure reflects a milestone payment from our oncology collaboration with Eisai.
1

-- 25 of 38 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 26 of 38 --

Driving value for patients and shareholders by progressing our pipeline
27
Key regulatory milestones
since the last earnings call:
Key data presentations
since the last earnings call:
• 	In the U.S., received approval for KEYTRUDA
in cervical cancer based on KN-826,
KEYTRUDA+Lenvima in RCC based on
KN-581, and WELIREG in certain types of
VHL-associated tumors. FDA granted
priority review for KEYTRUDA as adjuvant
therapy both in melanoma based on KN-716
and in RCC based on KN-564. FDA accepted
for review an sBLA for KEYTRUDA in
endometrial carcinoma based on KN-158
• 	In the EU, received approval for KEYTRUDA
in TNBC based on KN-355 as well as received
positive CHMP opinion for KEYTRUDA for
RCC based on KN-581 and endometrial based
on KN-775 and for VAXNEUVANCE in adults
• 	In China, received approval for KEYTRUDA in
esophageal or GEJ cancer based on KN-590
• 	In Japan, received approval for KEYTRUDA
in TNBC based on KN-355 and in MSI-H
colorectal cancer based on KN-177
• 	Announced data from broad oncology portfolio
at ESMO, including KEYTRUDA (KN-716,
KN-826, KN-355, KN-564, KN-775, KN-158,
KN365, and KN-522), Lynparza (OReO) and
WELIREG in VHL associated RCC
• 	Presented data from the Phase 2b trial studying
once-daily oral combination of doravirine and
islatravir for the treatment HIV at EACS
• 	Toplined data for the combination of doravirine
and islatravir for the treatment of HIV in the
switch setting from Protocols 17 and 18
• 	Announced positive results for KEYTRUDA in
Asian patients with HCC based on KN-394 and
Lynparza in metastatic castration resistant
prostate cancer based on PROpel
• 	Toplined pivotal results for VAXNEUVANCE in
infants based on the PNEU-PED trial, as well as
for molnupiravir in at-risk, non-hospitalized
adult patients with mild-to-moderate COVID-19
based on the MOVe-OUT trial

-- 27 of 38 --

Molnupiravir MOVe-OUT trial
28
• 	Global study with planned interim analysis that
evaluated 775 patients with at least one risk factor
for severe disease
• 	Reduced the risk of hospitalization or death by
~50% compared to placebo for at risk patients with
mild or moderate COVID-19
• 	Based on the participants with available viral
sequencing data, demonstrated consistent efficacy
across viral variants Gamma, Delta, and Mu
• 	Being evaluated for post-exposure prophylaxis to
prevent spread of COVID-19 within households in
Phase 3 study, MOVe-AHEAD
• 	Zero deaths reported compared to eight deaths on
placebo through Day 29
Patients with mild-to-moderate COVID-19
who experienced hospitalization or death:
7.3% of patients who
received molnupiravir
14.1% of patients who
received a placebo
Covid-19
Covid-19
1
1
1 7.3% represents 28/385 patients; 14.1% represents 53/377 patients

-- 28 of 38 --

Sotatercept is highly complementary to and strengthens
our existing cardiovascular portfolio and pipeline
29
Verquvo and Adempas are part of a collaboration with Bayer
Heart Failure 	Pulmonary Hypertension 	Anti-thrombotic 	Atherosclerosis
sotatercept 	MK-5475 	MK-2060 	MK-0616
Status Approved;
additional studies
planned
Approved 	Phase 3 	Phase 2/3 	Phase 2 	Phase 1
Mechanism
of Action
Oral sGC
stimulator
Oral sGC
stimulator
Activin receptor
type IIA fusion
protein
Inhaled sGC
stimulator Factor XI 	Oral PCSK9
Disease Area 	HFrEF PAH,
CTEPH
PAH,
PH-LHD PAH 	Thrombosis 	Atherosclerosis

-- 29 of 38 --

HIV and Vaccines highlights
30
• Doravirine and islatravir demonstrated
continued maintenance of viral suppression
in Phase 2 study through week 144
• Positive top-line results from pivotal Phase 3
study evaluating a once daily oral regimen of
doravirine and islatravir in switch setting
• Initiated Phase 2 study evaluating a once weekly
oral combination of islatravir and lenacapavir in
partnership with Gilead
• Positive CHMP opinion for VAXNEUVANCE
• ACIP unanimously voted to provisionally
recommend VAXNUEVANCE in series with
PNEUMOVAX 23 as an option for pneumococcal
vaccination pending CDC adoption
– Two dose regimen provides broadest serotype
coverage with 4 unique serotypes
– Only newly licensed PCV evaluated in a high-risk
immunocompromised patient population
• Positive top-line pivotal results for
VAXNEUVANCE in the pediatric setting and
submitted filing to FDA
Pneumococcal Disease	HIV

-- 30 of 38 --

Oncology highlights
31
• Approval of KEYTRUDA + chemotherapy in
recurrent or metastatic cervical cancer [KN-826]
• Presented significant new and updated data at
ESMO:
– Final results of KEYTRUDA + chemotherapy in
metastatic triple negative breast cancer
[KN-355]
– Data in expanded population across endometrial
cancer [KN-775 and KN-158]
• Positive top-line results in metastatic castration-
resistant prostate cancer for Lynparza +
abiraterone in front line setting [PROpel]
• Robust Phase 3 clinical development program
evaluating KEYTRUDA in combination in multiple
settings:
– KEYTRUDA + Lynparza 2nd / 3rd line mCRPC [KL-10]
– KEYTRUDA + docetaxel 1st / 2nd line mCRPC [KN-921]
– KEYTRUDA + enzalutamide 1st line mCRPC [KN-641]
– KEYTRUDA + enzalutamide+ADT in mHSPC [KN-991]
Women’s Cancers 	Prostate Cancer

-- 31 of 38 --

Broad based program in renal cell carcinoma
32
Future growth opportunities
in renal cell carcinoma
and more …
KEYTRUDA
FDA Priority
Review in
Adjuvant RCC
KEYTRUDA
+ Lenvima
APPROVED
in 1L aRCC
WELIREG
APPROVED in
VHL associated
RCC, CNS, pNET
KEYTRUDA +
axitinib
APPROVED
in 1L aRCC
WELIREG
3 Ph3 mono &
combo trials w/
KEYTRUDA
and/or
Lenvima
• 	APPROVED as first-in-class HIF-2α inhibitor
therapy targeting a gene transcription factor
• 	3 pivotal clinical trials in progress assessing
efficacy alone and in combination with TKI &
IO in advanced renal cell carcinoma
WELIREG
• 	1L advanced RCC Approvals:
– KEYTRUDA + Lenvima [KN-581]
– KEYTRUDA + axitinib [KN-426]
• 	Adjuvant RCC in Priority Review:
– KEYTRUDA [KN-564]
KEYTRUDA

-- 32 of 38 --

33
Lung
KN-091
KN-671
Breast
KN-242
KN-756
Women’s cancers
KL-001 (OVARIAN)
KN-A18 (CERVICAL)
KN-B21 (ENDOMETRIAL)
Esophageal
KN-975
Head & neck
KN-412
KN-689
Bladder
KN-057
KN-676
KN-866
Gastric
KN-585
Renal
KN-564
Liver
KN-937
LEAP012
Skin
KN-054
KN-716
KN-630
Potential foundational early-stage disease
program across many tumor types
KN-522
OLYMPIA
Approved Indication 	FDA Granted Priority Review
KN-867
KL-012
KN-905
KN-992
KN-B15

-- 33 of 38 --

Q&A
Rob Davis
Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Frank Clyburn
President, Merck Human Health
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 34 of 38 --

Appendix
35

-- 35 of 38 --

Q3 2021 GAAP financial results summary:
36
Q3 2021 	Q3 2020 	Change Change
Ex-FX
Sales 	$13.2 	$10.9 	+20% 	+19%
Operating Expenses 	$4.8 	$5.4 	-12% 	-12%
Tax Rate 	13.2% 	14.0% 	-0.8pts 	N/A
GAAP EPS from
continuing operations $1.80 	$0.92 	+96% 	+93%
$ in billions, except EPS amounts

-- 36 of 38 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V116
Pneumococcal, adult
V184
Chikungunya Virus
MK-1654
Respiratory Syncytial Virus
Vaccines
Infectious diseases
MK-8189
Schizophrenia
Neuroscience Gefapixant (MK-7264)
Cough (US, JPN, EU)
CUBICIN (MK-3009)
cSST & Sepsis, pediatric (JPN)
NOXAFIL (MK-5592)
Invasive aspergillosis (EU)
General medicine
General medicine
As of October 27, 2021
V114
Pneumoconjugate Vaccine, adult (EU,JPN)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-7075
Overgrowth Syndrome
MK-1942
Treatment Resistant Depression
MK-3655
NASH
MK-6024
NASH
MK-8591B (islatravir/MK-8507)
HIV-1 Infection
MK-8591D (islatravir/lenacapavir)
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary Tract
Cervical (EU)
cSCC (EU)
Gastric (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
Prostate
SCLC
MK-1308A
RCC
MK-7684A
NSCLC
LENVIMA (MK-7902)
HNSCC
Melanoma
CRC
Esophageal
NSCLC
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
CRC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
MK-3475 subcutaneous
NSCLC
MK-8591A (doravirine/islatravir)
HIV-1 Infection
Islatravir (MK-8591)
HIV-1 prevention
KEYTRUDA (MK-3475)
MSI-H or dMMR Endometrial (US)
TMB-H (JPN)
Adjuvant RCC (US, EU, JPN)
Advanced Unresectable Metastatic Esophageal (JPN)
Melanoma (US, EU)
High-risk early stage TNBC (EU, JPN)
Cervical (JPN)
LENVIMA (MK-7902)
1L HCC (US)
Advanced unresectable RCC (EU, JPN)
Advanced endometrial (EU, JPN)
MK-5475
Pulmonary Arterial Hypertension
MK-2060
Cardiovascular
Cardiovascular Molnupiravir (MK-4482)
COVID-19 (US, EU)
Infectious diseases
KEYTRUDA (MK-3475)
Advanced Solid Tumors
LYNPARZA (MK-7339)
Advanced Solid Tumors
MK-6440
Breast
NSCLC
SCLC
HNSCC
Esophageal
Gastric
Prostate
Melanoma
MK-1026
Hematological Malignancies
V937
Melanoma
Breast
CSCC
HNSCC
Solid Tumors
MK-4280A
(favezelimab/
pembrolizumab)
RCC
SCLC
WELIREG (MK-6482)
Rare Cancers
CRC
Pancreatic
Biliary
Certain VHL tumors (EU)
MK-4280
NSCLC
Hematological Malignancies
LENVIMA (MK-7902)
Biliary Tract
Glioblastoma
Prostate
SCLC
Pancreas
MK-7684A (vibostolimab/
pembrolizumab)
Biliary
Cervical
Esophageal
Breast
Endometrial
Prostate
Hematological Malignancies
MK-1308A
(quavonlimab/
pembrolizumab)
Advanced Solid Tumors
HCC
CRC
SCLC
Melanoma
TUKYSA (MK-7119)
Advanced Solid Tumors
Colorectal
Gastric
Endometrial
NSCLC
Bladder
Biliary
Cervical
MK-2140
Breast
NSCLC
MK-4830
NSCLC
SCLC
MK-0482
NSCLC
MK-1308
NSCLC
MK-5890
NSCLC
SCLC
MK-7684
Melanoma
Broad and innovative pipeline to solve significant unmet medical needs
37

-- 37 of 38 --

Capital allocation: TTM
~$ 20B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
$8.6
$4.7
$7.3 	$7.1
$0
$2
$4
$6
$8
$10
After-Tax R&D 	CapEx 	Dividend
& Share
Repurchase
Business
Development
(ex-divestitures)
Billions
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$1.40
$1.70
$2.00
$2.30
$2.60
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021E
Dollars per share
+11% 	+2% 	+2% +2% 	+2% 	+2%
+11%
+15%
+7%
Order of priority
Over the past 12 months
Capital investments
2021 to 2025
Commitment to the dividend
38
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities

-- 38 of 38 --